STUTTGART, Germany I July 21, 2025 I La Merie Publishing released its newest product entitled: TL1A Inhibitors & DR3 Antagonists: a Competitor Analysis ...

Scientists developed a fast, cell-free system to create virus-mimicking vaccines, enabling quicker responses to emerging ...

Researchers from Cornell and Northwestern universities have developed a rapid, cell-free method for building nanoparticle ...

Transmembrane proteins (TPs), also referred to as ‘integral membrane proteins’, make up between 70 % and 80 % of the total ...

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 receptor agonist. High-profile endorsements, including from Elon Musk, have ...

Researchers from Cornell and Northwestern universities have developed a rapid, cell-free method for building nanoparticle vaccines that mimic viruses ...

A new once daily triple drug treatment for cystic fibrosis is set to be “immediately funded” by NHS England following recommendation from the National Institute for Health and Care Excellence (NICE).1 ...

Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...

Licensed for use in the UK in March, Alyftrek will now be immediately funded by the NHS in England. This rapid timeline demonstrates NICE's commitment to getting breakthrough treatments to patients ...